Bayer Plc

Industry / private company


Location: Newbury, United Kingdom (GB) GB

ISNI: -

ROR: https://ror.org/05emrqw14

Show on Map:

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Combination effect of FInerenone and EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: Baseline clinical characteristics (2025) Agarwal R, Green JB, Heerspink HJ, Mann JF, McGill JB, Mottl AK, Rosenstock J, et al. Journal article Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis. (2023) Agarwal R, Tu W, Farjat AE, Farag YM, Toto R, Kaul S, Lawatscheck R, et al. Journal article Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE) (2022) Green JB, Mottl AK, Bakris G, Heerspink HJL, Mann JFE, Mcgill JB, Nangaku M, et al. Journal article Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis (2019) Becker M, Graf N, Sauter R, Allanore Y, Curram J, Denton CP, Khanna D, et al. Journal article Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort (2019) Wu W, Jordan S, Graf N, Pena JDO, Curram J, Allanore Y, Matucci-Cerinic M, et al. Journal article Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial (2015) Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, et al. Journal article